NASDAQ:EARS - Auris Medical Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.30
▼ -0.09 (-3.77%)
Get New Auris Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EARS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EARS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Auris Medical in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.30.

This chart shows the closing price for EARS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Auris Medical. This rating has held steady since December 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/20/2018Roth CapitalInitiated CoverageBuy$100.00High
10/8/2018Eurobank EFGInitiated CoverageBuy ➝ Buy$50.00High
7/1/2017Roth CapitalReiterated RatingBuy$100.00Low
4/13/2017Roth CapitalInitiated CoverageBuy ➝ Buy$90.00Medium
3/14/2017Needham & Company LLCLower Price TargetBuy$100.00 ➝ $80.00High
11/11/2016JMP SecuritiesReiterated RatingHoldN/A
(Data available from 9/28/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Auris Medical logo
Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.
Read More

Today's Range

Now: $2.30
Low: $2.22
High: $2.43

50 Day Range

MA: $2.88
Low: $2.25
High: $3.27

52 Week Range

Now: $2.30
Low: $0.73
High: $6.60

Volume

161,037 shs

Average Volume

3,096,183 shs

Market Capitalization

$26.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Auris Medical?

The following Wall Street analysts have issued research reports on Auris Medical in the last twelve months: Zacks Investment Research.
View the latest analyst ratings for EARS.

What is the current price target for Auris Medical?

0 Wall Street analysts have set twelve-month price targets for Auris Medical in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Auris Medical in the next year.
View the latest price targets for EARS.

What is the current consensus analyst rating for Auris Medical?

Auris Medical currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for EARS.

How do I contact Auris Medical's investor relations team?

Auris Medical's physical mailing address is Clarendon House 2 Church Street, Hamilton D0, HM 11. The biotechnology company's listed phone number is (441) 295-5950 and its investor relations email address is [email protected] The official website for Auris Medical is www.aurismedical.com.